| pubmed-article:15304598 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C0377265 | lld:lifeskim |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C0032893 | lld:lifeskim |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:15304598 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:15304598 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15304598 | pubmed:dateCreated | 2004-8-12 | lld:pubmed |
| pubmed-article:15304598 | pubmed:abstractText | In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period. Two hundred forty-five (69.2%) patients remained on LEV, with 8.8% achieving remission and some improvement in seizure control in 49.3%. Sedation was the most common adverse effect (10.7%), but mood disturbance was more likely to lead to discontinuation (4.8%). Cumulative probability of remaining on LEV at 12 months was 0.74 (95% CI 0.69 to 0.79). Factors predictive of a poorer retention were a greater number of previous antiepileptic drugs and a faster initial titration regimen. | lld:pubmed |
| pubmed-article:15304598 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15304598 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15304598 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15304598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15304598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15304598 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15304598 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15304598 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15304598 | pubmed:issn | 1526-632X | lld:pubmed |
| pubmed-article:15304598 | pubmed:author | pubmed-author:SmithDavid... | lld:pubmed |
| pubmed-article:15304598 | pubmed:author | pubmed-author:NicolsonAndre... | lld:pubmed |
| pubmed-article:15304598 | pubmed:author | pubmed-author:LewisSheila... | lld:pubmed |
| pubmed-article:15304598 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:15304598 | pubmed:day | 10 | lld:pubmed |
| pubmed-article:15304598 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:15304598 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15304598 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15304598 | pubmed:pagination | 568-70 | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:meshHeading | pubmed-meshheading:15304598... | lld:pubmed |
| pubmed-article:15304598 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15304598 | pubmed:articleTitle | A prospective analysis of the outcome of levetiracetam in clinical practice. | lld:pubmed |
| pubmed-article:15304598 | pubmed:affiliation | Department of Neurology, Hope Hospital, Stott Lane, Salford M6 8HD, UK. andrew@nicolson71.freeserve.co.uk | lld:pubmed |
| pubmed-article:15304598 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15304598 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15304598 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15304598 | pubmed:publicationType | Clinical Trial, Phase IV | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15304598 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15304598 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15304598 | lld:pubmed |
